10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Voloridge Investment Management LLC

Voloridge Investment Management LLC increased its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,585,965 shares of the company's stock after buying an additional 171,161 shares during the quarter. Voloridge Investment Management LLC owned about 1.31% of 10x Genomics worth $22,774,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. FMR LLC raised its position in 10x Genomics by 0.6% in the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock valued at $193,206,000 after purchasing an additional 86,455 shares during the period. ARK Investment Management LLC grew its stake in shares of 10x Genomics by 11.1% in the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after buying an additional 1,193,712 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of 10x Genomics in the fourth quarter valued at $47,092,000. Two Sigma Investments LP grew its stake in shares of 10x Genomics by 291.2% in the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after buying an additional 982,203 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of 10x Genomics by 240.6% in the fourth quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock valued at $17,752,000 after buying an additional 873,200 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

Shares of TXG traded up $0.06 during trading hours on Wednesday, hitting $8.65. The stock had a trading volume of 680,644 shares, compared to its average volume of 2,384,227. The firm has a market cap of $1.07 billion, a P/E ratio of -5.67 and a beta of 1.94. The company's fifty day simple moving average is $8.52 and its 200 day simple moving average is $11.95. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. The business had revenue of $154.88 million for the quarter, compared to analyst estimates of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The business's quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the company posted ($0.50) EPS. As a group, sell-side analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TXG shares. Stephens reissued an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. UBS Group lowered their target price on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday. Citigroup lowered their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group lowered their price objective on 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a research report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $15.81.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 4,044 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $33,565.20. Following the transaction, the chief financial officer now directly owns 331,588 shares of the company's stock, valued at $2,752,180.40. This trade represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 7,485 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $62,125.50. Following the completion of the transaction, the insider now directly owns 448,374 shares in the company, valued at $3,721,504.20. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,872 shares of company stock valued at $173,238 over the last three months. 9.39% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.